Introduction {#sec1-1}
============

Breast cancer is the most common cancer in women around the world (Ferlay et al., 2015) including Iranian women, however, the prevalence age of Iranian women for this disease is ten years below the prevalence age of women in advanced and developed countries (Yavari et al., 2003; Harirchi et al., 2004). 30-40% of breast cancer patients experience metastasis during their follow-up. The pique of recurrence is 2 to 3 years after treatment (Dawood et al., 2010; Fodor et al., 2011).

Despite the incurability of metastatic disease, identifying the methods to promote increased survival and improved quality of life for patients with metastatic breast cancer is the main objective of the studies that have been done so far in this field. The goal of this retrospective study is to investigate the factors influencing the survival of patients with recurrent breast cancer.

In previous studies, factors such as biological characteristics of tumor and the comparison of different subtypes (luminal A, B), HER2 positive and triple negative were studied. Also, there were studies on the effects of lymph node status, surgical method, disease stage, patient age, DFI on the evaluation of tumor's tendency towards metastasis. However, the effects of these factors on the survival of patients after recurrence have been given more attention in this study. Previous studies investigating the effective factors of survival in metastatic breast cancer patients, the factors included the place of metastasis, the extent of metastasis (visceral metastasis vs. bone metastases), HER2 receptor and performance status.

DFI, the previous adjuvant treatment and metastatic therapy have been effective in survival of patients (Beslija et al., 2009). Some studies also found that factors such as age, black race, socioeconomic status and BMI were effective on survival (Hortobagyi et al., 1983; Vincent et al., 1986; Bradley et al., 2002; Berclaz et al., 2004; Grau et al., 2005; Lagerlund et al., 2005; Loi et al., 2005; Tao et al., 2005; Whiteman et al., 2005; Bouchardy et al., 2006; Dalton et al., 2006; Caan et al., 2008; Cluze et al., 2009; Rezaianzadeh et al., 2009).

In fact, different studies did not report the same risk factor and effective factor, thus, more studies are needed in different societies in order to find more effective factors while finding more effective solutions in order to increase patients' survival.

Materials and Methods {#sec1-2}
=====================

This study was performed on 442 recurrent breast cancer patients who had been referred to the Cancer Research Center of the Shahid Beheshti University between 1985 to 2015. After initial treatment, including surgical and adjuvant therapy, 442 patients experienced recurrence during the follow-up. Upon confirmation of cancer recurrence; loco-regional recurrence, visceral metastasis and bone metastasis were treated and patients were followed up. At the end of the follow-up period the factors influencing survival after recurrence were evaluated based on patient's death or condition in the last visit.

Patients' information was extracted from the records of Shahid Beheshti Cancer Research Center, which included demographic data (age), tumor characteristics (tumor size, estrogen receptor status, progesterone, HER2), stage of disease, lymph vascular invasion, lymph node status, nodal ratio (ie. the ratio of the number of involved lymph nodes to the total number of removed lymph nodes), primary surgery method (mastectomy or breast preservation surgery), the location of metastasis, DFI (disease free survival), adjuvant treatments (chemotherapy and Radiotherapy). Subsequently, the effect of these factors on survival (the time between the diagnosis of metastasis and the occurrence of death or not in the last visit at the end of the follow-up period (2016, March 19th)) was evaluated using the analysis of univariate and multivariate Stratified cox-model.

In Statistical analysis Using a stratified Cox proportional hazards model to assess the patient's age at the time of diagnosis, disease stage, lympho-vascular invasion, primary tumor size, lymph node involvement, DFI (disease free survival), the location of metastasis (visceral, bone, loco-regional), biological categorization of tumors including luminal A (ER and PR Positive and HER2 negative), luminal B (ER and PR positive and HER2 positive), HER2 n reach (ER and PR negative and HER2 positive) and triple negative (ER and PR and HER2 negative) on survival was applied using univariate and multivariate analyses and P values of 0.05. We used 0.25 cut-off point to analyze the nodal ratio which was proved in previous study (21.22) and Kaplan Meyer curve of survival was drawn based on effective factors on survival after recurrence ([Figure 1](#F1){ref-type="fig"}). Comparison of survival was performed in a different categorization using a log -rank test. [Table 3](#T1 T2 T3){ref-type="table"}: life table performed for 2,5years survival
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###### 

Prognostic Factors for Survival in Recurrent Breast Cancer Patients (Univariate Cox Regression Analysis)

  Factors                                                  Haz. Ratio   p\>z    95%con.interval
  -------------------------------------------------------- ------------ ------- ---------------------
  Age                                                                           
   \<40                                                    1                    
   \>=40                                                   2.675737     0.041   1.041227-6.876087
  Stage                                                                         
   1                                                       1                    
   2                                                       1.176159     0.697   0.5197839-2.661396
   3                                                       1.759438     0.14    0.8309554-3.725378
  Grade                                                                         
   1                                                       1                    
   2                                                       1.394477     0.503   0.5272838-3.687891
   3                                                       2.512724     0.066   0.9399615-6.717065
  LVI [\*](#t1f1){ref-type="table-fn"}                                          
   negative                                                1                    
   positive                                                2.10547      0.561   1.248773-3.549886
  Receptors                                                                     
   Luminal A[\*\*](#t1f2){ref-type="table-fn"}             1                    
   Luminal B[\*\*\*](#t1f3){ref-type="table-fn"}           1.842634     0.085   0.9184965-3.696584
   Triple negative[\*\*\*\*](#t1f4){ref-type="table-fn"}   1.482221     0.268   0.7385408-2.974758
   Her2 n reach[\*\*\*\*\*](#t1f5){ref-type="table-fn"}    1.739194     0.12    0.8659807-3.492914
  Tumor size                                                                    
   \<2cm                                                   1                    
   2-5cm                                                   1.016194     0.959   0.548013-1.884352
   \>5cm                                                   1.256021     0.502   0.6457379-2.443081
  Lymph node                                                                    
   Negative                                                1                    
   Positive\<4node                                         2.337451     0.008   1.249909-4.371266
   Positive\>4=node                                        2.745066     0       1.574971-4.78446
  DFI[\*\*\*\*\*\*](#t1f6){ref-type="table-fn"}                                 
   \<2year                                                 1                    
   \>=2year                                                0.6323073    0.018   0.4328129-0.9237537
  Chemotherapy                                                                  
   Negative                                                1                    
   Positive                                                2.313931     0.46    0.2494663-21.46293
   Radiotherapy                                                                 
   Positive                                                1.616843     0.463   0.448723-5.825821
  Place                                                                         
   loco regional                                           1                    
   Bon                                                     1.924987     0.066   0.9568276-3.872771
   Visceral                                                4.027297     0       2.242385-7.232979
  Surgery                                                                       
   BCS 1                                                   1                    
   MRM 2                                                   1.129304     0.599   0.7176197-1.777165
  Nodal ratio                                                                   
   \<0.25                                                  1                    
   \>0.25                                                  2.026603     0.002   .28655-3.192351

Lymph vascular invasion;

ER and PR and her2 receptor are positive;

ER and PR are positive and her2 is negative;

ER and PR and her2 are negative;

ER and PR are negative and her2 is positive;

disease free survival; 1, breast conserving surgery 2, modified radical mastectomy.

###### 

Prognostics Factors for Survival in Recurrent Breast Cancer Patients (Multivariate Cox Regression Analysis)

  Factors             Haz.Ratio   p\>z    95%con.interval
  ------------------- ----------- ------- --------------------
  Age                                     
   \<40               1                   
   \>=40              0.0058437   0.253   8.70e-7-3924609
  Stage                                   
   1                                      
   2                  3.420663    0.819   0.00909-128716.9
   3                  2.88E-12            
  Tumor size                              
   \<2cm              1                   
   2-5cm              0.0855957   0.652   1.99e-06-3690.573
   \>5cm              0.7908029   0.94    0.0016913-369.7621
  Lymph node                              
   negative           1                   
   Positive\<4 node   4.58E+11    0       1.26e+09-1.67e+14
   Positive\>=4node   3.63E+13    0       7.44e+10-1.78e+16
  DFI                                     
   \<2year            1                   
   \>=2year           0.8660959   0.909   0.743554-10.08834
  Surgery                                 
   BCS                1                   
   MRM                0.319669    0.13    0.0037-2.2762072
  Place                                   
   Loco regional      1                   
   Bon                4.17E+11    0       2.73e+10-6.37e+12
   Visceral           3.93E+11    0       
  Receptors                               
   Luminal A          1                   
   Luminal B          4.127313    0.363   0.1949789-87.36695
   Triple negative    2.197177    0.686   0.484883-99.56191
   Her2 nreach        6.559239    0.24    0.2442123-151.3785
  LVI                                     
   negative           1                   
   positive           0.148506    0.194   0.0083319-2.646926
  Nodal Ratio                             
   \<0.25             1                   
   \>=0.25            0.100675    0.089   0.000503-2.013802

###### 

Life Table

  interval   Beq.Total   Deaths   Lost   Survival   Std.Error   95% con.int.
  ---------- ----------- -------- ------ ---------- ----------- ----------------
  o-2 year   278         119      75     0.5052     0.0322      0.4404 -0.5664
  2-5 year   84          33       36     0.2526     0.035       0.1870-0.3232
  \>5 year   15          3        12     0.1684     0.0461      0.0901-0.2675

The analysis was performed using the STATA software version 16. This study have been performed in accordance with Declaration of Helsinki.

Results {#sec1-3}
=======

Of 3449 breast cancer patients who had been referred to the Cancer Research Center of Shahid

Beheshti University between 1985 and 2015, 442 patients had recurrences.

This study was performed on 442 patients with breast cancer recurrence. The mean age of recurrent people was 50 years (24-90 years) and the mean survival was 1.6 years after recurrence (5 days -13 years). 219 patients (70.42 %) survived for two years, 75 patients (12.22%) survived between 2-5 years, and 17 patients (5.47%) survived more than 5 years; in 131 patients, the survival was unknown.

The average follow-up period of patients was 45 months (38 months, 10 months), of which 155 died during this period.

47.96% of the distant metastasis included 41% bone metastasis, 22.16% lung metastasis, 14.22% liver metastasis, 16.5% brain metastasis, 47.0% spleen metastasis and 4.7% other cases, 93 patients (43.86%) had loco-regional recurrence. The mean survival after loco-regional recurrence was 24 months, while it lasted for 22 months in bone recurrence and 15.6 months in visceral recurrence. The mean survival after recurrence in a variety of biomarkers including luminal A and B was 20 months while it lasted for 14 months in patients with triple negative, 24 months in HER2 +. [Table 1](#T1){ref-type="table"} prognostic factors for survival in recurrent breast cancer patients (Univariate cox regression analysis)

Factors such as age, stage of disease, primary grade of tumor, lympho-vascular invasion, the primary tumor size, lymph node metastasis, DFI (disease free survival), adjuvant therapy (chemotherapy and radiotherapy), the location of recurrence (visceral, bone, loco-regional) and nodal ratio analysis were evaluated using univariate and multivariate analyses. The result of this analysis is shown in[Table 2](#T2){ref-type="table"}:Prognostics factors for survival in recurrent breast cancer patients (Multivariate cox regression analysis).

the univariate analysis of Cox regression model has shown the most important factors with a negative impact on survival in metastatic patients including age more than 40 years (p = 0.041), lymph node involvement (p = 0.000), visceral recurrence (p = 0.000) compared to the bone recurrence and loco-regional recurrence while the DFI \<2 years (p = 0.018) and (p = 0.002) nodal ratio\> 0.25. Yet, in the multivariate analysis of the most important factors included visceral recurrence (p = 0.000), status of lymph node involvement (p = 0.000) while nodal ratio in the multivariate analysis showed no effect on survival after recurrence.

Discussion {#sec1-4}
==========

Several studies have shown that the age of diagnosis is a major contributor to survival, which means that patients over 50 years of age have a worse prognosis (Khanfir et al., 2013). In our study, based on univariate analysis, the age of more than 40 years had a negative effect on survival after recurrence. The importance of DFI (disease free survival), i.e. the period without disease after breast cancer treatment to the recurrence, is known to be a major contributor to recurrence. It has been proven in numerous studies that patients with a long DFI have better prognosis (Blanco et al., 1990; Bastholt et al., 1996; Dhodapkar et al., 1996; Cardoso et al., 2002). In this study, the effect of DFI on survival after recurrence was also observed in the univariate analysis. DFI \<2 years had a negative effect on survival after recurrence.

In our study on univariate and multivariate analysis, the location of metastasis has the most important effect on survival prediction, thus, visceral metastasis has a more negative effect on survival while bone metastasis has worse prognosis compared to loco-regional recurrence. This result is also evident in previous studies reporting that prognosis of patients with visceral metastasis has been proven to be worse than those with bone metastasis (Vogel et al., 1992; Bastholt et al., 1996; Venturini et al., 1996; Chang et al., 2003; Truong et al., 2005).

Another important and different outcome of this study was the effect of lymph node involvement on survival after recurrence. Several studies have been conducted on the negative effects of nodal ratio on breast cancer patients concerning their increased risk of metastasis reporting that those with a nodal ratio of\> 0.25 had worse prognosis. This ratio enjoyed a more prognostic value than just the number of lymph nodes (Veronesi et al., 1993). In a study conducted by Dr. Tazhibi and his colleagues in Iran, in patients with metastatic breast cancer and NR\> 0.25 the risk of subsequent metastasis increased and patients survive for a less period of time (Tausch et al., 2012).

However, in our study, lymph node involvement, regardless of its number, had a negative effect on survival after recurrence, and nodal ratio was not effective in multivariate analysis. In fact, patients with less than 4 lymph nodes or with more involvement received equal negative effects on their survival after recurrence, (compared to the patients with negative lymph nodes). Although the number of lymph nodes in these patients influenced their increased risk of recurrence, lymph node involvement regardless of its number reduces survival after recurrence.

Also, in this study, the primary surgical method (mastectomy or breast preservation surgery) has not been shown to have an effect on survival. The effect of primary adjuvant treatments (radiotherapy and chemotherapy) has not been proven on survival, which may be due to the fact that about 80% of patients received chemotherapy and radiotherapy. This effect was not measurable in two groups. One of the limitations in this study was the lack of evaluation for the effects of radiotherapy, chemotherapy and hormone therapy in patients after recurrence, mostly due to lack of data in this area.

The status of hormone receptors (estrogen, progesterone, HER2 receptor, triple negative) has been shown in several studies reporting that the patients with luminal A and B have a better prognosis than the patients with triple negative(Hess et al., 2003; Tazhibi et al., 2013). In a series of studies of the patients with HER2 + after recurrence, it was reported that they had better prognosis than other biomarkers (Bertucci et al., 2008; Sparano et al., 2012; Weide et al., 2014). However, in this study, the effect of biological factors on survival evaluation after recurrence has not been proven in the multivariate and univariate analyses. Patients with HER2 positive had a prolonged mean survival after recurrence, so that the mean survival after recurrence in the patients with luminal A and B was 20 months while the triple negatives were 15 months. Yet, the patients with HER2 positive had a survival of 24 months, which could be due to the effect of anti her2 treatment. Several studies have highlighted the effect of this treatment on increasing the survival of HER2 positive patients while suggesting that the treatment with trastuzumab as a humanized monoclonal antibody targeting HER2 receptor, also increases DFS, OVERAL SURVIVAL both in the adjuvant and metastatic phases(Verma et al., 2012; Cadoo et al., 2013).

This study did not evaluate the effect of metastatic adjuvant therapy and surgical treatment of breast tumor in patients with metastatic in primary breast cancer. In fact, we examined the effect of some factors on the survival of metastatic breast cancer patients. Further investigation in this field are still needed.
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